Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2948313 | 0.98 | HCAR2 (0.55) | HCAR2CHRNA4TDP1LMNAMME | |
| SCHEMBL2759528 | 0.84 | CHRNA4 (0.50) | HCAR2CHRNA4TDP1LMNAMME | |
| SCHEMBL1190827 | 0.82 | CHRNA4 (0.50) | HCAR2CHRNA4TDP1LMNAMME | |
| SCHEMBL1536321 | 0.82 | CHRNA4 (0.52) | HCAR2CHRNA4MMEALDH1A1KDM4E | |
| SCHEMBL2637696 | 0.82 | CHRNA4 (0.49) | HCAR2CHRNA4MMEALDH1A1KDM4E | |
| SCHEMBL12674209 | 0.79 | CHRNA4 (0.47) | HCAR2CHRNA4MMEALDH1A1KDM4E | |
| SCHEMBL12835947 | 0.79 | SMN1; SMN2 (0.51) | HCAR2CHRNA4MMEALDH1A1KDM4E | |
| SCHEMBL2722839 | 0.79 | HCAR2 (0.52) | HCAR2CHRNA4TDP1ALDH1A1HPGD | |
| SCHEMBL15004534 | 0.79 | CHRNA4 (0.47) | CHRNA4MMEALDH1A1KDM4EMAPT | |
| SCHEMBL9963197 | 0.79 | HCAR2 (0.52) | HCAR2CHRNA4ALDH1A1SMPD1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 290 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755963-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | claimed |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | claimed |
| US-9260408-B2 | Dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-02-16 | — | — | US | claimed |
| EP-2635567-B1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2015-10-28 | — | — | EP | claimed |
| US-20150065516-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2015-03-05 | — | — | US | claimed |
| EP-2668155-B1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-11-26 | — | — | EP | claimed |
| EP-2755963-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-23 | — | — | EP | claimed |
| EP-2668155-A2 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-04 | — | — | EP | claimed |
| US-8592426-B2 | Aryl-benzocycloalkyl amide derivatives | Hoffmann—La Roche Inc. (US) | 2013-11-26 | — | — | US | claimed |
| EP-2658848-A1 | NEW BIARYL AMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-11-06 | — | — | EP | claimed |
| EP-2635567-A1 | INDOLE DERIVATIVES | Richter Gedeon Nyrt. (HU) | 2013-09-11 | — | — | EP | claimed |
| US-20130217702-A1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT. | 2013-08-22 | — | — | US | claimed |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CINCOR PHARMA, INC. | 2013-03-21 | — | — | US | claimed |
| WO-2013037779-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | claimed |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | US | claimed |
| WO-2012101011-A2 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | claimed |
| WO-2012089601-A1 | NEW BIARYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-05 | — | — | WO | claimed |
| US-20120165338-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-06-28 | — | — | US | claimed |
| WO-2012059776-A1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2012-05-10 | — | — | WO | claimed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| CN-119998278-A | Compounds and uses thereof | 福宏治疗公司 | 2025-05-13 | — | — | CN | disclosed |
| EP-4522278-A1 | BENZOYPARAZINE PYRAZINES ANE THEIR USES | Foghorn Therapeutics Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-3653618-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-01-08 | — | — | EP | disclosed |
| EP-3885340-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2024-11-27 | — | — | EP | disclosed |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-09-19 | — | — | US | disclosed |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-27 | — | — | US | disclosed |
| CN-112204009-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-05-07 | — | — | CN | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4308575-A1 | MACROCYCLES AS CFTR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023220129-A1 | BENZOYPARAZINE PYRAZINES ANE THEIR USES | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220129-A1 | BENZOYPARAZINE PYRAZINES ANE THEIR USES | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116981672-A | Macrocyclic compounds as CFTR modulators | 爱杜西亚药品有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| EP-3452456-B1 | BICYCLIC MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-109369635-B | Compound or pharmaceutically acceptable salt thereof, application thereof and pharmaceutical composition | 赛克里翁治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-11634413-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230106002-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-11584738-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| CN-109641854-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20230012262-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| CN-109384778-B | Use of a compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease, health condition or disorder | 赛克里翁治疗有限公司 | 2022-12-13 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022194399-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-22 | — | — | WO | disclosed |
| CN-110016020-B | Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof | 赛克里翁治疗有限公司 | 2022-07-26 | — | — | CN | disclosed |
| EP-3998260-A1 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-07 | — | — | US | disclosed |
| US-20220106281-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2022-04-07 | — | — | US | disclosed |
| EP-3660013-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210401808-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-12-30 | — | — | US | disclosed |
| US-20210401808-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-12-30 | — | — | US | disclosed |
| US-11207323-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11174219-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174219-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3885340-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2021-09-29 | — | — | EP | disclosed |
| US-11124502-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-09-21 | — | — | US | disclosed |
| CN-108912111-B | Compounds and pharmaceutical compositions | 赛克里翁治疗有限公司 | 2021-09-14 | — | — | CN | disclosed |
| US-11046713-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2021-06-29 | — | — | US | disclosed |
| US-11033533-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-06-15 | — | — | US | disclosed |
| US-11033533-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210155576-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210155576-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| EP-3369732-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | IPS HEART | 2021-02-25 | — | — | US | disclosed |
| US-10913727-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2021-02-09 | — | — | US | disclosed |
| CN-112204009-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-01-08 | — | — | CN | disclosed |
| US-10829438-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829438-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200345727-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-05 | — | — | US | disclosed |
| EP-3259255-B1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20200316065-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200299307-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2020-09-24 | — | — | US | disclosed |
| EP-3710428-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2020-09-23 | — | — | EP | disclosed |
| CN-107250119-B | (2R,4R) -5- (5 '-chloro-2' -fluorobiphenyl-4-yl) -2-hydroxy-4- [ (5-methyloxazole-2-carbonyl) amino ] pentanoic acid | 施万生物制药研发IP有限责任公司 | 2020-09-22 | — | — | CN | disclosed |
| US-20200283422-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-10 | — | — | US | disclosed |
| US-20200281900-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-10 | — | — | US | disclosed |
| US-20200281900-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-10 | — | — | US | disclosed |
| US-10711013-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2020-07-14 | — | — | US | disclosed |
| EP-3660013-A1 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3653618-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2020-05-20 | — | — | EP | disclosed |
| US-10639308-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-10570120-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-10548879-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-02-04 | — | — | US | disclosed |
| US-10548879-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-02-04 | — | — | US | disclosed |
| EP-2755963-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | disclosed |
| US-20190276442-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190269659-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190269659-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-09-05 | — | — | US | disclosed |
| US-10315984-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-06-11 | — | — | US | disclosed |
| US-10315984-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-06-11 | — | — | US | disclosed |
| US-20190167679-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190135772-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2019-05-09 | — | — | US | disclosed |
| US-20190100536-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2019-04-04 | — | — | US | disclosed |
| EP-3452456-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10189823-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-10183021-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-10172834-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-10172834-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180327350-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-11-15 | — | — | US | disclosed |
| EP-2858650-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2018-11-14 | — | — | EP | disclosed |
| US-10118933-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2018-11-06 | — | — | US | disclosed |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | disclosed |
| EP-3199517-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-3369732-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2018-09-05 | — | — | EP | disclosed |
| US-9981999-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981999-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981999-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3056485-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2018-05-09 | — | — | EP | disclosed |
| US-9884807-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884807-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884807-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-02-06 | — | — | US | disclosed |
| US-9873685-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873685-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-9872855-B2 | (2R,4R)-5-(5′-Chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-9872855-B2 | (2R,4R)-5-(5′-Chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-9872855-B2 | (2R,4R)-5-(5′-Chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3259255-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | Theravance Biopharma R&D IP, LLC (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20170362260-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362260-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362260-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170355664-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355664-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355664-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170349574-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170349574-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-07 | — | — | US | disclosed |
| WO-2017193063-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES (US) | 2017-11-09 | — | — | WO | disclosed |
| US-20170260206-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2017-09-14 | — | — | US | disclosed |
| EP-3199517-A1 | NEPRILYSIN INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3199517-A1 | NEPRILYSIN INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20170196841-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170196841-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170196841-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-07-13 | — | — | US | disclosed |
| EP-2822953-B9 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2822953-B9 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER (US) | 2017-06-21 | — | — | EP | disclosed |
| US-9683002-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9683002-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9683002-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9670140-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670140-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670186-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670186-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670140-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9657003-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2017-05-23 | — | — | US | disclosed |
| US-20170137439-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136019-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| EP-2864292-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-2864292-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9586937-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-2822953-B1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2822953-B1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER (US) | 2017-02-01 | — | — | EP | disclosed |
| US-9533962-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-9533962-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160375022-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-12-29 | — | — | US | disclosed |
| EP-2882716-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20160347738-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9481689-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| WO-2016133803-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016133803-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-25 | — | — | WO | disclosed |
| US-20160244416-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160244416-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160244416-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-25 | — | — | US | disclosed |
| EP-3056485-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | Orion Corporation (FI) | 2016-08-17 | — | — | EP | disclosed |
| US-20160090393-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160090393-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160090393-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160083372-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083372-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-24 | — | — | US | disclosed |
| US-9260408-B2 | Dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20160031903-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2970243-A2 | SGC STIMULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20160002148-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002148-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002148-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-01-07 | — | — | US | disclosed |
| EP-2635567-B1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2015-10-28 | — | — | EP | disclosed |
| US-9133215-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133215-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133215-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2015-09-15 | — | — | US | disclosed |
| WO-2015132141-A1 | 1,3-OXAZINE-2-AMINE DERIVATIVES ACTING AS BACE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-11 | — | — | WO | disclosed |
| US-9126956-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126956-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-08 | — | — | US | disclosed |
| US-9108934-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108934-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108934-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150203479-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION | 2015-07-23 | — | — | US | disclosed |
| US-20150119571-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-04-30 | — | — | US | disclosed |
| US-20150119571-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-04-30 | — | — | US | disclosed |
| US-20150119571-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-04-30 | — | — | US | disclosed |
| EP-2864292-A1 | NEPRILYSIN INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2858650-A1 | NEPRILYSIN INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2015-04-15 | — | — | EP | disclosed |
| US-8975254-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2015-03-10 | — | — | US | disclosed |
| US-20150065516-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150065516-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150065516-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2015-03-05 | — | — | US | disclosed |
| US-8952176-B2 | Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-8952176-B2 | Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| EP-2822953-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Pfizer Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| US-8912221-B2 | Biaryl amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912221-B2 | Biaryl amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912221-B2 | Biaryl amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-12-16 | — | — | US | disclosed |
| EP-2668155-B1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-11-26 | — | — | EP | disclosed |
| US-8871792-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871792-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871792-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| WO-2014144100-A2 | SGC STIMULATORS | NAKAI TAKASHI (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2755963-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| EP-2493858-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2014-07-02 | — | — | EP | disclosed |
| US-20140135339-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135339-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135339-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8680111-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680111-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680111-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2014-02-13 | — | — | US | disclosed |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2014-02-13 | — | — | US | disclosed |
| WO-2014025891-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| WO-2013184898-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-12-12 | — | — | WO | disclosed |
| US-20130330365-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-12-12 | — | — | US | disclosed |
| US-20130330366-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-12-12 | — | — | US | disclosed |
| WO-2013184934-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-12-12 | — | — | WO | disclosed |
| EP-2668155-A2 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| US-8592426-B2 | Aryl-benzocycloalkyl amide derivatives | Hoffmann—La Roche Inc. (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2658848-A1 | NEW BIARYL AMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-11-06 | — | — | EP | disclosed |
| US-20130252961-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252961-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2013132376-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| EP-2635567-A1 | INDOLE DERIVATIVES | Richter Gedeon Nyrt. (HU) | 2013-09-11 | — | — | EP | disclosed |
| US-20130217702-A1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT. | 2013-08-22 | — | — | US | disclosed |
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| EP-2401256-B1 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2013-04-17 | — | — | EP | disclosed |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CINCOR PHARMA, INC. | 2013-03-21 | — | — | US | disclosed |
| WO-2013037779-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| WO-2012131031-A1 | NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | WO | disclosed |
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | US | disclosed |
| US-20120225867-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2012-09-06 | — | — | US | disclosed |
| EP-2493858-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | Orion Corporation (FI) | 2012-09-05 | — | — | EP | disclosed |
| WO-2012101011-A2 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012089601-A1 | NEW BIARYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-05 | — | — | WO | disclosed |
| US-20120165338-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-06-28 | — | — | US | disclosed |
| US-20120165338-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-06-28 | — | — | US | disclosed |
| US-20120165338-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-06-28 | — | — | US | disclosed |
| WO-2011051540-A9 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2012-06-21 | — | — | WO | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012059776-A1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2012-05-10 | — | — | WO | disclosed |
| EP-2188254-B1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-03-21 | — | — | EP | disclosed |
| EP-2401256-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| EP-2396301-A2 | SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS | Jerini AG (DE) | 2011-12-21 | — | — | EP | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2011051540-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011025690-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-03-03 | — | — | WO | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| WO-2010097372-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097373-A1 | COMPOUNDS FOR USE AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010091876-A2 | SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS | JERINI AG (DE) | 2010-08-19 | — | — | WO | disclosed |
| US-20100197662-A1 | HETEROCYCLIC COMPOUND HAVING TYPE I 11 BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197662-A1 | HETEROCYCLIC COMPOUND HAVING TYPE I 11 BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| EP-2188254-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-05-26 | — | — | EP | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009027450-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-05 | — | — | WO | disclosed |
| EP-1723143-B1 | AMINO CYCLOPROPANE CARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | MERCK & CO INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20070189865-A1 | Amino cyclopropane carboxamide derivatives as bradykinin antagonists | MERCK & CO., INC. | 2007-08-16 | — | — | US | disclosed |
| EP-1723143-A2 | AMINO CYCLOPROPANE CARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Merck & Co., Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005085198-A2 | AMINO CYCLOPROPANE CARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | MERCK & CO., INC. (US) | 2005-09-15 | — | — | WO | disclosed |
| EP-0590789-B9 | Excitatory amino acid receptor antagonists | LILLY CO ELI (US) | 2004-02-04 | — | — | EP | disclosed |
| EP-0590789-B1 | Excitatory amino acid receptor antagonists | LILLY CO ELI (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-0695748-B1 | Tetrazolinone herbicides | BAYER AGROCHEM KK (JP) | 1999-05-06 | — | — | EP | disclosed |
| US-5675008-A | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1997-10-07 | — | — | US | disclosed |
| US-5670516-A | NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-09-23 | — | — | US | disclosed |
| US-5648492-A | Process for preparing isoquinoline compounds | ELI LILLY AND COMPANY (US) | 1997-07-15 | — | — | US | disclosed |
| US-5637712-A | CATALYTIC HYDROGENNATION | ELI LILLY AND COMPANY (US) | 1997-06-10 | — | — | US | disclosed |
| US-5606062-A | STEREOSELECTIVE REDUCTION | ELI LILLY AND COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| US-5589439-A | HERBICIDES | NIHON BAYER AGROCHEM K.K. (JP) | 1996-12-31 | — | — | US | disclosed |
| EP-0695748-A1 | Tetrazolinone herbicides | NIHON BAYER AGROCHEM K.K. (JP) | 1996-02-07 | — | — | EP | disclosed |
| US-5399696-A | Excitatory amino acid receptor antagonists; nervous system disorders | ELI LILLY AND COMPANY (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0399645-B1 | Tetrahydropyranyl derivatives, process for their preparation and pharmaceutical or veterinary compositions containing them | BEECHAM GROUP PLC (GB) | 1994-11-09 | — | — | EP | disclosed |
| EP-0590789-A1 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1994-04-06 | — | — | EP | disclosed |
| US-5284957-A | Substituted 1H- or 2H-tetrazoles | ELI LILLY AND COMPANY (US) | 1994-02-08 | — | — | US | disclosed |
| EP-0399645-A2 | Tetrahydropyranyl derivatives, process for their preparation and pharmaceutical or veterinary compositions containing them | BEECHAM GROUP PLC (GB) | 1990-11-28 | — | — | EP | disclosed |
| EP-0399645-A2 | Tetrahydropyranyl derivatives, process for their preparation and pharmaceutical or veterinary compositions containing them | BEECHAM GROUP PLC (GB) | 1990-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244416-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | MME, DNPEP, TMPRSS15 | HCAR2 132/4885CHRNA4 661/4885TDP1 3682/4885 |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | HCAR2 1825/4885CHRNA4 4851/4885TDP1 1824/4885 |
| US-20150065516-A1 | NEW BIARYL AMIDE DERIVATIVES | BICRA, HDAC10, BRD7 | HCAR2 494/4885CHRNA4 2611/4885TDP1 2697/4885 |
| US-20230106002-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | HCAR2 1415/4885CHRNA4 2941/4885TDP1 711/4885 |
| US-20160002148-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 845/4885CHRNA4 1174/4885TDP1 864/4885 |
| US-11584738-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | HCAR2 50/4885CHRNA4 2491/4885TDP1 4039/4885 |
| US-20150119571-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 890/4885CHRNA4 1415/4885TDP1 860/4885 |
| US-20170260206-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | HCAR2 364/4885CHRNA4 1393/4885TDP1 3907/4885 |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | EXOSC9, EXOSC5, EXOSC4 | HCAR2 4792/4885CHRNA4 2449/4885TDP1 478/4885 |
| US-10172834-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | MME, DNPEP, TMPRSS15 | HCAR2 135/4885CHRNA4 690/4885TDP1 3710/4885 |
| US-20130217702-A1 | INDOLE DERIVATIVES | BDKRB1, BDKRB2, ARRB1 | HCAR2 134/4885CHRNA4 823/4885TDP1 2685/4885 |
| US-20200283422-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 658/4885CHRNA4 1359/4885TDP1 787/4885 |
| US-11174219-B2 | Neprilysin inhibitors | MME, REN, ACE | HCAR2 845/4885CHRNA4 1174/4885TDP1 864/4885 |
| US-20170137439-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | HCAR2 1415/4885CHRNA4 2941/4885TDP1 711/4885 |
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | HCAR2 1304/4885CHRNA4 2240/4885TDP1 2237/4885 |
| US-10548879-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | MME, DNPEP, TMPRSS15 | HCAR2 135/4885CHRNA4 690/4885TDP1 3710/4885 |
| US-10118933-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | HCAR2 364/4885CHRNA4 1393/4885TDP1 3907/4885 |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | HCAR2 126/4885CHRNA4 578/4885TDP1 3348/4885 |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 658/4885CHRNA4 1359/4885TDP1 787/4885 |
| US-20130252961-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, EML4 | HCAR2 4256/4885CHRNA4 3659/4885TDP1 3490/4885 |
| US-20130330366-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 845/4885CHRNA4 1174/4885TDP1 864/4885 |
| US-20190269659-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | MME, DNPEP, TMPRSS15 | HCAR2 132/4885CHRNA4 661/4885TDP1 3682/4885 |
| US-11207323-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | HCAR2 1415/4885CHRNA4 2941/4885TDP1 711/4885 |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | EXOSC5, UTRN, EXOSC4 | HCAR2 4764/4885CHRNA4 1395/4885TDP1 549/4885 |
| US-20100197662-A1 | HETEROCYCLIC COMPOUND HAVING TYPE I 11 BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | HSD11B1, HSD3B1, HSD11B2 | HCAR2 991/4885CHRNA4 1442/4885TDP1 2640/4885 |
| US-10913727-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | HCAR2 2061/4885CHRNA4 4385/4885TDP1 2489/4885 |
| US-20160090393-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 890/4885CHRNA4 1415/4885TDP1 860/4885 |
| US-10639308-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | HCAR2 1415/4885CHRNA4 2941/4885TDP1 711/4885 |
| US-20170362260-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 890/4885CHRNA4 1415/4885TDP1 860/4885 |
| US-20160083372-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 658/4885CHRNA4 1359/4885TDP1 787/4885 |
| US-20170196841-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | MME, DNPEP, TMPRSS15 | HCAR2 132/4885CHRNA4 661/4885TDP1 3682/4885 |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | CYP1A1, AHR, CYP1B1 | HCAR2 492/4885CHRNA4 2451/4885TDP1 2783/4885 |
| US-20140135339-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, EML4 | HCAR2 4256/4885CHRNA4 3659/4885TDP1 3490/4885 |
| US-20160347738-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | HCAR2 1415/4885CHRNA4 2941/4885TDP1 711/4885 |
| US-10829438-B2 | Neprilysin inhibitors | MME, REN, ACE | HCAR2 845/4885CHRNA4 1174/4885TDP1 864/4885 |
| US-20180327350-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 845/4885CHRNA4 1174/4885TDP1 864/4885 |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | CFTR, PKD1, ARRB1 | HCAR2 1198/4885CHRNA4 1133/4885TDP1 4270/4885 |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | HCAR2 2061/4885CHRNA4 4385/4885TDP1 2489/4885 |
| US-20210155576-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 845/4885CHRNA4 1174/4885TDP1 864/4885 |
| US-10315984-B2 | Neprilysin inhibitors | MME, REN, ACE | HCAR2 845/4885CHRNA4 1174/4885TDP1 864/4885 |
| US-20200281900-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | MME, DNPEP, TMPRSS15 | HCAR2 132/4885CHRNA4 661/4885TDP1 3682/4885 |
| US-10711013-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | HCAR2 364/4885CHRNA4 1393/4885TDP1 3907/4885 |
| US-20200299307-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | HCAR2 364/4885CHRNA4 1393/4885TDP1 3907/4885 |
| US-20220106281-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | HCAR2 2061/4885CHRNA4 4385/4885TDP1 2489/4885 |
| US-20170355664-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 845/4885CHRNA4 1174/4885TDP1 864/4885 |
| US-10183021-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | HCAR2 1415/4885CHRNA4 2941/4885TDP1 711/4885 |
| US-20210401808-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | MME, DNPEP, TMPRSS15 | HCAR2 132/4885CHRNA4 661/4885TDP1 3682/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | HCAR2 315/4885CHRNA4 48/4885TDP1 2895/4885 |
| US-20170136019-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | HCAR2 1415/4885CHRNA4 2941/4885TDP1 711/4885 |
| US-20160375022-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | HCAR2 1415/4885CHRNA4 2941/4885TDP1 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.